MSN Laboratories Ltd, a fast growing active pharmaceutical ingredients and formulations company of India is planning to invest Rs.150 crore for setting up an API, formulations and CRAMS (Contract Research and Manufacturing Services) unit in Hyderabad.

Started small with a single unit in the year 2003, today the Hyderabad based MSN Group has established 8 units across India of which 6 are manufacturing units catering to APIs, 1 unit for formulations and 1 research and development centre. Out of the 6 manufacturing units 3 units are US FDA certified while the remaining 3 are catering to ROW (Rest of the World) and Indian markets.

While sharing his views with Pharmabiz, Dr MSN Reddy, CMD of MSN group of companies, revealed his expansion plans and said that the MSN group is planning to invest a total of Rs.150 crore in the first phase to set up an exclusive API, Formulations and CRAMS unit in Hyderabad. “We are a vertically integrated company and our main focus is global markets. At present we are growing consistently with a year-on-year growth of 30-40 per cent. Our major strength is our people, focused R&D and cGMP practices” said Dr Reddy.

The year 2012 was a great year for the MSN Group. The Group achieved a growth target of 40 per cent. The overall turnover of the Group by March 2012 was set at Rs.600 crore and by the end of the financial year march 2013 it is expected that it will cross Rs.1000 crore. So far the Group has filed 148 Drug Master Files (DMFs) globally of which 74 DMFs are filed in USA and other 74 are filed in EU.

Airing his future plans Dr MSN Reddy said, “We are planning to launch 2 important molecules in EU and USA by 2015. Our research is mainly focused on the development of molecules and not on therapeutics. At present we are having 3-4 potential molecules which can give us a competitive advantage and our success lies in winning new markets with new molecules.”

The MSN Group of companies has been recognized globally and has been approved and certified by all countries as quality and safety complier. Very soon the group is planning to develop a Green field facility for its formulations unit in a plot of over 40 acres in Hyderabad. The company is already having a patient portfolio of 150 drugs in different countries. It is also planning to file 35 more patents in USA and 40 patents in EU in the coming days.